CURRENT STORY VALIDATION 6 November 2026 - review edition 6 National items and regional directions were recomputed from the existing prototype_data.json, itself derived from all 24 detailed dispensing files and reconciled with the competition extract. Six SSRI medicine changes sum exactly to +31,471 items. Regional sertraline changes sum to +69,538; citalopram changes sum to -37,514. All 14 annual sertraline changes are positive and all 14 annual citalopram changes are negative. MATCHED-MONTH OMISSION CHECK For each of 14 areas, exclude January from BOTH years and compare the remaining medicine counts; repeat for each calendar month. Sertraline increases survive 168 of 168 comparisons. Citalopram decreases survive 167 of 168. Exceptions (area, omitted month, resulting item difference): [('NHS Dumfries and Galloway', 5, 15)]. These are full-year descriptive results. The exception is disclosed, so no uninterrupted monthly decline or universal process is claimed. No causal inference or patient-switching analysis was performed. Review edition 6 adds descriptive medians/IQRs/ranges, monthly-share and calendar-day sensitivity checks, and exploratory exact area-sign tests with Holm correction across all six SSRIs. Their independent-area model is explicitly conditional; see ssri_statistical_methods.txt and ssri_statistics.json. The tests were developed after examining the data. RELATED SHARE CHECK FROM THE EARLIER EXPLORATION Sertraline's share of SSRI items is 49.3468887% to 50.6269907%, +1.280102 percentage points. The annual share direction remains positive after every matched-month omission in every area. That is a distinct measure from percentage change in a medicine's own count. Historical area-level share sensitivity results remain in ssri_pattern_sensitivity.csv; they must not be mislabelled as the new count-omission check. COUNTS, COSTS AND SOURCES The extraction audit covers 35,534,316 rows and 621,942 pharmacy/month/chapter combinations, with no item mismatches or cost differences above 2p. See dispensing_analysis_notes.txt. This is community dispensing-location activity, all ages. There is no person-level clinical information. Cost means are not treatment-cost comparisons. See prescribing_cost_context.txt. REVIEW AND ENTRY STATUS Reader feedback and clinical framing review have not been supplied in this chat. There is no clinical endorsement. Do not submit until reader feedback has been reviewed and the user explicitly says the entry is ready to submit. Publishing a review link is separate from entering the competition.